# EDGAR Filing Document

**Accession Number:** 0001293818
**File Stem:** 0001079973-23-000099
**Filing Date:** 2023-1
**Character Count:** 6734
**Document Hash:** 9ccd168205e0ac5f871c3f7a3d5944e0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001079973-23-000099.hdr.sgml**: 20230120

**ACCESSION NUMBER**: 0001079973-23-000099

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230119

**ITEM INFORMATION**: Changes in Registrant's Certifying Accountant

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230120

**DATE AS OF CHANGE**: 20230120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OPGEN INC
- **CENTRAL INDEX KEY:** 0001293818
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **IRS NUMBER:** 061614015
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37367
- **FILM NUMBER:** 23541454

**BUSINESS ADDRESS:**
- **STREET 1:** 9717 KEY WEST AVENUE
- **STREET 2:** SUITE 100
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 301-869-9683

**MAIL ADDRESS:**
- **STREET 1:** 9717 KEY WEST AVENUE
- **STREET 2:** SUITE 100
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

?xml version="1.0" encoding="utf-8"?

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**_________________**

**FORM 8-K**

**_________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

 **January 19, 2023 Date of Report (date of earliest event reported)**

**_________________**

**OpGen, Inc.**

**(Exact name of Registrant as specified in its charter)**

**_________________**

---

| | | |
|:---|:---|:---|
|  **Delaware**<br> **(State or other jurisdiction of incorporation or organization)** | **001-37367**<br> **(Commission** <br> **File Number)** | **06-1614015**<br> **(I.R.S. Employer<br> Identification Number)** |

---

**9717 Key West Ave** **, Suite 100 Rockville, MD 20850 (Address of principal executive offices)(Zip code)**

**(301) 869-9683 (Registrant's telephone number, including area code)**

**Not Applicable (Former name or former address, if changed since last report)**

**_________________**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock | OPGN | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 4.01 Changes in Registrant's Certifying Accountant.**

On January 19, 2023, CohnReznick LLP ("CohnReznick"), OpGen, Inc.'s (the "Company") current independent public accounting firm, notified the Company that CohnReznick would decline to stand for re-appointment after completion of the audit for the fiscal year ended December 31, 2022. In light of such determination, the Company is currently in the process of identifying a successor independent registered public accounting firm and will disclose its engagement of a new independent registered public accounting firm once the selection process has been completed, as required by the rules and regulations of the U.S. Securities and Exchange Commission ("SEC").

CohnReznick's audit reports on the Company's consolidated financial statements as of and for the fiscal years ended December 31, 2021 and 2020 did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope or accounting principles, except that the reports contained an explanatory paragraph stating that there was substantial doubt about the Company's ability to continue as a going concern.

During the fiscal years ended December 31, 2021 and 2020 and the subsequent interim period through January 18, 2023, there were no: (1) disagreements with CohnReznick on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements, if not resolved to their satisfaction, would have caused them to make reference in connection with their opinion to the subject matter of the disagreement, or (2) reportable events under Item 304(a)(1)(v) of Regulation S-K.

In accordance with Item 304(a)(3) of Regulation S-K, the Company provided CohnReznick with a copy of the disclosures in this Current Report on Form 8-K prior to filing with the SEC and requested that CohnReznick furnish the Company with a letter addressed to the SEC stating whether it agrees with the above statements. A copy of CohnReznick's letter dated January 20, 2023, stating that they agree with the statements made herein, is attached as Exhibit 16.1 hereto and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

&nbsp;&nbsp;&nbsp;&nbsp;16.1 [Letter from CohnReznick regarding change in certifying accountant](ex16x1.htm)

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: January 20, 2023 | **OpGen, Inc.** | **OpGen, Inc.** | **OpGen, Inc.** |
|  | By: | /s/ Albert Weber | /s/ Albert Weber |
|  |  | Name: | Albert Weber |
|  |  | Title: | Chief Financial Officer |

---

## Exhibit 16.1

Exhibit 16.1

January 20, 2023

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Ladies and Gentlemen:

We have read Item 4.01 of Form 8-K dated January 20, 2023 of OpGen, Inc. and are in agreement with the statements contained therein.

/s/ CohnReznick LLP